Eloxx Pharmaceuticals announced that the first patients have now been dosed in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. Topline results are expected in the first half of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELOX:
- Eloxx announces first patients enrolled in Phase 2 study of ELX-02
- Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
- Biotech Alert: Searches spiking for these stocks today
- Eloxx Pharmaceuticals price target lowered to $50 from $120 at Oppenheimer